期刊文献+

广东省氯氮平治疗药物监测室间质评实施的研究 被引量:1

External Quality Assessment of Clozapine for Therapeutic Drug Monitoring in Guangdong Province
下载PDF
导出
摘要 目的:在广东省内对各精神专科医院进行氯氮平治疗药物监测(TDM)室间质量评价。方法:通过发放调查问卷的形式了解广东省内精神专科医院氯氮平治疗药物监测所使用高效液相色谱仪的相关参数,并通过发放统一质控品对省内各专科医院进行氯氮平治疗药物监测室间质量评价。结果:省内6家精神专科医院氯氮平TDM低、中、高浓度质控品的检测合格率分别为66.67%,66.67%,83.33%。结论:在省内开展氯氮平治疗药物监测室间质评是十分必要的。 Objective: To implement the external quality assessment (EQA) of clozapine for therapeutic drug monitoring (TDM) among psychiatric hospitals in Guangdong. Methods: The parameters of HPLC used by the hospitals were understood through questionnaires. The EQA of clozapine for TDM was implemented by distributing the quality control serum. Results: The qualified rate of clozapine in the quality control serum at low, medium and high concentrations for TDM was 66.67%, 66.67% and 83.33%, respectively. Conclusion: It is necessary to implement EQA of clozapine for TDM in Guangdong.
出处 《中国药师》 CAS 2016年第9期1791-1793,共3页 China Pharmacist
基金 中山市科技计划项目(编号:2014A1FC148)
关键词 氯氮平 治疗药物监测 质量控制 室间质评 Clozapine Therapeutic drug monitoring Quality control External quality assessment
  • 相关文献

参考文献10

  • 1de la Chapelle A, Kari C, Nurminen M, et al. Clozapine-induced a- granulocytosis. A genetic and epidemiologic study [ J ]. Hum genet, 1977, 37(2) : 183-194.
  • 2Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced a- granulocytosis. Incidence and risk factors in the United States[ J ]. N Engl J Med, 1993, 329(3) :162-167.
  • 3Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabe- tes[J].Am J Med, 2001, 111(9) : 716-723.
  • 4Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever [ J ]. Psychoneuroendocrinology, 2009, 34 ( 1 ) : 118-128.
  • 5Wahlbeek K, Cheine M, Essali A, et al. Evidence of clozapine~ ef- fectiveness in schizophrenia: a systematic review and meta-analysis of randomized triMs[J]. Am J Psychiatry, 1999, 156(7) : 990-999.
  • 6Hiemke C, Baumann P, Bergemanu N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [J]. Pharmacopsychiatry, 2011,44 ( 6 ) : 195-235.
  • 7Oo TZ, Wilson JF, Naidoo D, et al. Therapeutic monitoring of cloza- pine in Australia: the need for consensus [ J ]. Ther Drug Monit, 2006, 28(5): 696-699.
  • 8Fischer V, Haar JA, Greiner L, et al. Possible role of free radical formation in clozapine (clozaril) -induced agranulocytosis [ J ]. Molec- ular pharmacology, 1991,40(5 ) ; 846-853.
  • 9Grllnder G, Baumann P, Conca A, et al. Therapeutic drug monito- ring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP[J]. Ner~enarzt, 2014, 85(7) : 847-855.
  • 10Shah VP, Midha KK, Dighe S, et al. Analytical methods validation : bioavailability, bioequivalence and pharmacokinetic studies. Confer- ence report [J]. Eur J Drug Metab Pharma~okinet, 1991,16 (4) : 249 -255.

同被引文献9

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部